cas 1099-45-2|| where to buy Ethyl 2-(triphenylphosphoranylidene)acetate

Nom du produit:Ethyl 2-(triphenylphosphoranylidene)acetate

IUPAC Name:ethyl 2-(triphenyl-λ⁵-phosphanylidene)acetate

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM247704-1000g	in stock	ǧƙȦ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1099-45-2 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:1099-45-2; Formule moléculaire:C22H21O2P; Point de fusion:-; Code SMILES:C3=C([P](C1=CC=CC=C1)(C2=CC=CC=C2)=CC(OCC)=O)C=CC=C3; Densité:

: Numéro de catalogue:CM247704; Poids moléculaire:348.38; Point d'ébullition:490.4°C at 760 mmHg; N° Mdl:MFCD00009183; Stockage:Keep in Inert atmosphere, store at 2-8°C.

: Catalysts and Ligands; A catalyst refers to a substance that increases the rate of a reaction without changing the overall standard Gibbs free energy change of the reaction. Ligands represent atoms, molecules, and ions that can bond with a central atom (metal or metalloid). In general, ligands will donate at least one electron when participating in a bond. Two-phase catalysis of catalysts and ligands is the first application in the field of fluorine chemistry. The method of self-fluorine two-phase catalysis has developed rapidly, and a large number of new fluorine-based catalysts and ligands (especially phosphines) have been obtained in the field of chemistry.; catalysts factory; Chemenu has professional catalysts factory,we wish to create splendid achievements with you in the future.

: Fenebrutinib; Roche’s investigational drug, Fenebrutinib has shown brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis (MS) from the recent release of new data from Phase II FENopta study. Fenebrutinib is a potent and highly selective Bruton’s tyrosine kinase (BTK) inhibitor, and currently the only reversible inhibitor being tested in Phase III MS trials. BTK inhibitor is involved in key pathological features of MS, including B-cell development and activation.